Supernus Pharmaceuticals Inc (SUPN)

Working capital turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	605,106	619,414	641,163	674,751	673,056	651,277	618,187	585,808	560,079	545,016	551,524	536,576	506,717	465,383	418,476	402,257	392,755	408,243	409,099	403,942
Total current assets	US$ in thousands	493,113	449,360	423,538	883,340	734,151	663,886	625,120	568,516	601,590	668,375	639,244	586,023	630,417	552,015	557,153	557,048	472,644	427,082	390,911	419,967
Total current liabilities	US$ in thousands	290,196	287,534	252,590	731,545	687,958	725,987	735,536	284,558	315,379	234,711	283,447	240,812	245,108	299,606	269,276	168,335	160,587	149,717	143,971	151,706
Working capital turnover		2.98	3.83	3.75	4.45	14.57	—	—	2.06	1.96	1.26	1.55	1.55	1.32	1.84	1.45	1.03	1.26	1.47	1.66	1.51

December 31, 2023 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $605,106K ÷ ($493,113K – $290,196K)
= 2.98

Supernus Pharmaceuticals Inc's working capital turnover has shown fluctuating trends over the recent quarters. In Q4 2023, the working capital turnover was 2.99, which was lower than the ratios in Q3 and Q2 of the same year (3.77 and 3.71, respectively). However, it was higher compared to the working capital turnover in Q1 2023, which was 4.40.

Notably, the working capital turnover in Q4 2022 was significantly higher at 14.44 compared to the recent quarters, indicating a more efficient utilization of working capital at that time. Furthermore, there is no data available for working capital turnover in Q3 and Q2 of 2022.

Overall, a higher working capital turnover ratio indicates that the company is effectively using its working capital to generate sales. It is important to monitor trends in this ratio over time to assess the company's efficiency in managing its working capital.